| Bina Patel, | |
|
1001 Rohlwing Rd, Elk Grove Village, IL 60007-3217 | |
| (847) 524-8800 | |
| Not Available |
| Full Name | Bina Patel |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 1001 Rohlwing Rd, Elk Grove Village, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063285591 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bina Patel, 1001 Rohlwing Rd, Elk Grove Village, IL 60007-3217 Ph: () - | Bina Patel, 1001 Rohlwing Rd, Elk Grove Village, IL 60007-3217 Ph: (847) 524-8800 |
News Archive
Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.
A national research team led by UC Davis Health clinicians and researchers from the University of Michigan, Nationwide Children's Hospital and Columbia University, has derived and validated a new protocol for emergency departments that can determine which infant patients with fevers, age 60 days or younger, are at low risk of significant bacterial infections.
GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.
People suffering from chronic non-cancer pain and severe emotional distress, such as depression, anxiety and substance use, are likely to receive long-term opioid therapy despite a lack of evidence that this treatment helps, reports a new review in General Hospital Psychiatry.
"The association is clear, even when controlling for risk factors such as substance abuse and mental illness," says Emma Björkenstam of the Swedish National Board of Health and Welfare and Doctoral Student at the medical university Karolinska Institutet.
› Verified 8 days ago